European Warehouse  /  VIP 001 Semaglux EU

VIP 001 Semaglux EU

5.0/5 · 6 reviews

Tax included where applicable. Shipping calculated at checkout.

Semaglutide is a GLP-1 receptor agonist with extensive Phase III clinical data. The STEP trial programme demonstrated up to 14.9% mean body weight reduction over 68 weeks. One of the most studied compounds in metabolic research, with regulatory approval for multiple indications.

Every batch is independently tested by a 3rd party laboratory. Certificate of Analysis available below.

Out of stock

This product is currently unavailable. Check the recommended alternatives below, or contact us for restock updates.

The more you buy, the more you save

Buy 5
-5%
discount
Buy 7
-7.5%
discount
BEST DEAL
Buy 10+
-10%
discount
View this batch CoA

Every batch is tested by an independent third-party laboratory with no commercial relationship to Camo Chem. We never self-certify. The full Certificate of Analysis is published on this page and verifiable directly with the testing lab.

Worldwide shipping. UK orders typically delivered in 1-3 working days. EU and international orders 3-7 working days. Tracked and signed-for delivery. Free shipping over £65 (UK) / €110 (EU) / $110 (US).

Store lyophilised powder in a cool, dry place. After reconstitution, refrigerate at 2-8°C.

Don't forget

Bacteriostatic water

Required for reconstituting lyophilised peptides. European Warehouse.

Reconstitution

Need help with dosing?

Calculate the exact volume of bacteriostatic water for your target dose.

Worldwide ShippingUK · EU · USA · Asia
3rd Party TestedIndependent lab CoA
≥98% HPLC PurityVerified per batch
Safe DeliveryDiscreet packaging
Compound Profile

VIP 001 Semaglux · GLP-1 Receptor Agonist

A GLP-1 receptor agonist with extensive Phase III clinical data. Demonstrated up to 14.9% body weight reduction in clinical trials. One of the most studied compounds in metabolic research.

Research Overview

About this compound

What does the research say?

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the action of the naturally occurring incretin hormone GLP-1. It activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon release, delay gastric emptying, and reduce appetite through central nervous system signalling.

In the STEP clinical trial programme, semaglutide produced mean body weight reductions of up to 14.9% over 68 weeks compared to placebo. The compound received regulatory approval for both type 2 diabetes and chronic weight management, becoming one of the most commercially significant peptide compounds in pharmaceutical history. Additional trials have investigated cardiovascular outcomes, showing a 20% reduction in major adverse cardiovascular events.

These are not marketing claims. These are peer-reviewed, published results. You can verify every reference below.

Why does quality matter?

Semaglutide is a complex 31-amino acid peptide with a fatty acid chain modification (C18 acyl chain) that extends its half-life to approximately 7 days. This modification must be correctly conjugated for the compound to have its characteristic extended duration of action.

At Camo Chem, every batch is tested by an independent 3rd party laboratory. We publish the full Certificate of Analysis for every batch, and you can verify the results directly with the lab. We do not self-certify. Ever.

Ask your current supplier: who tests their products?

Technical Data

Compound specifications

Common NamesSemaglutide
CAS Number910463-68-2
Molecular Weight4,113.58 g/mol
Amino Acids31 (with C18 fatty acid modification)
ClassificationGLP-1 receptor agonist
Purity≥98% (HPLC verified)
Content per Vial5 mg
Physical FormLyophilised (freeze-dried) white powder
SolubilitySoluble in water and bacteriostatic water
StoragePowder: cool, dry place. After reconstitution: 2-8°C.
Peer-reviewed Studies

Published research on Semaglutide

1

Up to 14.9% mean body weight reduction over 68 weeks versus placebo in the STEP clinical trial programme.

View on PubMed →
2

20% reduction in major adverse cardiovascular events in clinical trials.

View on PubMed →
3

Regulatory approval for both type 2 diabetes management and chronic weight management based on extensive Phase III data.

View on PubMed →
Customer Reviews

What researchers are saying

5.0
6 reviews
5★
6
4★
0
3★
0
2★
0
1★
0
matteo Verified

Quality and price top

Anonymous Verified

Works wonders with my two rats, recommended product.

Riccardo Verified

Ottimo prodotto! Soddisfa appieno le aspettative.

FAQ

Frequently asked questions

Semaglutide is a GLP-1 receptor agonist with CAS number 910463-68-2. It is a 31-amino acid peptide with a C18 fatty acid modification that extends its half-life to approximately 7 days. It has received regulatory approval for multiple indications. This product is sold exclusively as a research compound.

Every batch meets a minimum of 98% purity as verified by HPLC. Testing is performed by an independent 3rd party laboratory.

By an independent laboratory with no commercial relationship with our company. We do not self-certify.

Yes. Semaglutide is supplied as a lyophilised powder and must be reconstituted with bacteriostatic water before use.

In lyophilised form, store in a cool, dry place. After reconstitution, refrigerate at 2-8°C.

Ready to research?

Get Semaglux

≥98% HPLC purity, independently lab-verified, Certificate of Analysis included with every batch.

Currently out of stock
Shopping Cart